High cost of cancer care forcing many to compromise their health

According to the results of a survey conducted by the American Cancer Society Cancer Action Network (ACS CAN), the exorbitant costs of health care, as related to modern anticancer treatments, are overwhelming patients, forcing them to make tough decisions and potentially compromising their health.

A third of cancer patients or survivors under the age of 65 have found themselves uninsured at some point since diagnosed. Another third currently undergoing cancer treatment "have put off some type of health care in the past year" because of financial concerns. Many from this group have trouble covering health-care related costs such as health insurance premiums, co-pays and prescriptions;

Cancer can devastate a family's finances; one family in three affected by cancer has trouble covering bills for "basic necessities" (i.e. food and housing), while one in five families burn up virtually all their savings paying for cancer treatments.

For more results and conclusions from the ACS CAN poll, go to the American Cancer Society's pressroom.

By Ross Bonander

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap